Medicover Integrated Clinical Services Sp. z o.o
Medicover Integrated Clinical Services Sp. z o.o is recorded as a service provider in 20 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 20 trials · Latest update first
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
Sponsor ENYO Pharma
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Fifteen study centers were initiated, but 12 centers across the US, France, and Spain enrolled participants.
- The study enrolled 26 participants, exceeding the initially planned sample size of 20 to 24 participants.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Sponsor Artios Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Sponsor Can-Fite Biopharma Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
Sponsor Phenonet Inc.
- Start (EU)
- Latest update
- Estimated end
A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare
Sponsor Olatec Therapeutics LLC
- Start (EU)
- Latest update
- Estimated end
A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD)
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
Sponsor Alentis Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects with Moderate-to-Severe Plaque Psoriasis
Sponsor Can-Fite Biopharma Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections
Sponsor Bioaegis Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease
Sponsor H. Lundbeck A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
Sponsor Rophibio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Sponsor Taiho Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus fluconazole and placebo in the treatment of acute Candida vulvovaginitis
Sponsor Palau Pharma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by subcutaneous injection in nonambulatory participants with Duchenne Muscular Dystrophy
Sponsor Antisense Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
Sponsor Adeptio Pharmaceuticals Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Medicover Integrated Clinical Services Sp. z o.o?
The 2026-10-09 snapshot links Medicover Integrated Clinical Services Sp. z o.o to 20 distinct CTIS trials. Recorded services include Laboratory services, tissue block preparation, Collection and storage of clinical trial samples, Direct Coombs Test and Eluted Antibodies, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Medicover Integrated Clinical Services Sp. z o.o?
The most frequently recorded therapeutic areas are Gastroenterology, Cardiology, Genetic and Congenital Disorders, Gynecology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Medicover Integrated Clinical Services Sp. z o.o conducted?
The linked trials record locations in 15 countries, including Poland, Spain, Germany, France, Bulgaria. These are trial locations, not confirmed office locations or countries where Medicover Integrated Clinical Services Sp. z o.o delivered services.
What can this page tell me about Medicover Integrated Clinical Services Sp. z o.o's trial experience?
Browse 20 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Medicover Integrated Clinical Services Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Medicover Integrated Clinical Services Sp. z o.o.